Andrew Lerman, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $163,278 of the $249,311 with a category attached, or 65.5%. 60 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 41.6% of the total. Among epilepsy clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,562 payments — averaging $159.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$104K
- Amneal Pharmaceuticals LLC$34K
- Argenx US, Inc.$29K
- Neurelis, Inc.$23K
- AbbVie$16K
- MDD US Operations, LLC$10K
- plus $35K from 54 others
Across 82 payments — averaging $53,316 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.5M
- UCB SA$345K
- Novartis$312K
- Argenx US, Inc.$92K
- Takeda Pharmaceuticals U.S.A., Inc.$72K
- Amgen$29K
- plus $23K from 1 others
What the payments were for
- Consulting fees$36,70815%
- Speaking & faculty fees$163,27865%
- Travel & lodging$14,3496%
- Food & beverage$33,76214%
- Education$1,2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$249,311 in reported general payments places this provider in the 95th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 182 | $885,750 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 118 | $790,323 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 79 | $568,606 |
| NuplazidPimavanserin Tartrate | 63 | $336,632 |
| GocovriAmantadine Hcl | 136 | $285,954 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 14 | $267,854 |
| RytaryCarbidopa/Levodopa | 322 | $250,628 |
| IngrezzaValbenazine Tosylate | 25 | $220,509 |
| EpidiolexCannabidiol (Cbd) | 28 | $180,545 |
| Kesimpta PenOfatumumab | 12 | $124,708 |
| BotoxOnabotulinumtoxina | 84 | $117,132 |
| AubagioTeriflunomide | 11 | $101,157 |
| Nurtec OdtRimegepant Sulfate | 57 | $80,832 |
| AptiomEslicarbazepine Acetate | 25 | $64,880 |
| NuedextaDextromethorphan Hbr/Quinidine | 31 | $56,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $471 | $885,750182 claims |
| Grifols USA, LLCGamunex-C | $43 | $790,323118 claims |
| PfizerOctagam, Nurtec Odt, Eliquis | $837 | $357,22583 claims |
| Acadia Pharmaceuticals IncNuplazid | $162 | $336,63263 claims |
| MDD US Operations, LLCGocovri | $9,616 | $285,954136 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $103,686 | $270,44591 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $33,584 | $252,500353 claims |
| AbbVieBotox, Linzess, Ubrelvy | $16,070 | $173,362154 claims |
| SanofiAubagio | $152 | $101,15711 claims |
| UCB, Inc.Briviact, Vimpat, Neupro | $9,349 | $68,87155 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $395 | $64,88025 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $56 | $56,92831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Miami
- Alberto Pinzon ArdilaMiami$144K
- Miguel Melo-BicchiMiami$15K
- Carlos MillanMiami$7K
- Luis TornesMiami$6K
- Gisela Moreira EyngMiami$3K
- Brian CostellBoca Raton$469K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.